Pascal Soriot, chief executive officer of AstraZeneca. Picture: Simon Dawson/Bloomberg

A participant in AstraZeneca's coronavirus vaccine trial triggered a global
shutdown of the promising vaccine after she experienced worrying neurological
symptoms.